Alzheimer’s and aducanumab: Unjust profits and spurious hopes
Credit: CC0 Public Domain The U.S. Food and Drug Administration’s controversial decision to approve aducanumab for the medication of Alzheimer’s disease raises now not less than three most necessary ethical considerations that must be addressed, states a recent article within…